Exelixis Inc. Stock
Exelixis Inc. Stock
We can see a decrease in the price for Exelixis Inc.. Compared to yesterday it has lost -€0.360 (-1.010%).
With 32 Buy predictions and 1 Sell predictions Exelixis Inc. is one of the favorites of our community.
With a target price of 41 € there is a slightly positive potential of 14.49% for Exelixis Inc. compared to the current price of 35.81 €.
So far the community has only identified positive things for Exelixis Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | -1.010% | -3.995% | -3.607% | 1.073% | -7.035% | 132.050% | 91.129% |
| United Therapeutics | -0.290% | -3.333% | 0.268% | 44.476% | -3.604% | 77.238% | 207.388% |
| Iovance Biotherapeutics Inc. | 10.180% | 34.565% | 106.318% | 27.434% | 86.530% | -31.973% | -83.697% |
| Ligand Pharmaceuticals | 2.270% | 12.500% | 7.143% | 66.667% | 8.434% | 168.496% | 48.270% |
Comments
Exelixis (NASDAQ:EXEL) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $52.00 price target on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis (NASDAQ:EXEL) had its price target raised by analysts at HC Wainwright from $49.00 to $52.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
News
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade
Exelixis (NASDAQ: EXEL) is a relatively small biotech company with big dreams -- to become, as its executives said at a presentation in December, a "top five solid tumor oncology company."
The
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026
While not the most popular biotech company on the market, Exelixis (NASDAQ: EXEL) has been quietly making a name for itself over the past five years, while delivering strong financial results and
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?
Exelixis Inc. (NASDAQ: EXEL) stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. The company reported earnings per share (EPS) of 94
